Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo

Friedrich Koch-Nolte, Jan Reyelt, Britta Schößow, Nicole Schwarz, Felix Scheuplein, Stefan Rothenburg, Friedrich Haag, Vanina Alzogaray, Ana Cauerhff, Fernando A. Goldbaum

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The purpose of our study was to develop a tool for blocking the function of a specific leukocyte ecto-enzyme in vivo. ART2.2 is a toxin-related ectoenzyme that transfers the ADP-ribose moiety from NAD onto other cell surface proteins. ART2.2 induces T cell death by activating the cytolytic P2 X 7 purinoceptor via ADP-ribosylation. Here, we report the generation of ART2.2-blocking single domain antibodies from an immunized llama. The variable domain of heavy-chain antibodies (VHH domain) represents the smallest known antigen-binding unit generated by adaptive immune responses. Their long CDR3 endows VHH domains with the extraordinary capacity to extend into and block molecular clefts. Following intravenous injection, the ART2.2-specific VHH domains effectively shut off the enzymatic and cytotoxic activities of ART2.2 in lymphatic organs. This blockade was highly specific (blocking ART2.2 but not the related enzymes ART1 or ART2.1), rapid (within 15 min after injection), and reversible (24 h after injection). Our findings constitute a proof of principle that opens up a new avenue for targeting leukocyte ecto-enzymes in vivo and that can serve as a model also for developing new antidotes against ADP-ribosylating toxins.

Original languageEnglish (US)
Pages (from-to)3490-3498
Number of pages9
JournalFASEB Journal
Volume21
Issue number13
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Single-Domain Antibodies
ADP Ribose Transferases
New World Camelids
T-cells
T-Lymphocytes
Adenosine Diphosphate
Leukocytes
Enzymes
Adenosine Diphosphate Ribose
Purinergic Receptors
Antidotes
Injections
Adaptive Immunity
Cell death
Intravenous Injections
NAD
Membrane Proteins
Cell Death
Antigens
Antibodies

Keywords

  • ADP-ribosylation
  • Enzyme inhibitors
  • Leukocyte ecto-enzymes
  • Recombinant antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. / Koch-Nolte, Friedrich; Reyelt, Jan; Schößow, Britta; Schwarz, Nicole; Scheuplein, Felix; Rothenburg, Stefan; Haag, Friedrich; Alzogaray, Vanina; Cauerhff, Ana; Goldbaum, Fernando A.

In: FASEB Journal, Vol. 21, No. 13, 11.2007, p. 3490-3498.

Research output: Contribution to journalArticle

Koch-Nolte, F, Reyelt, J, Schößow, B, Schwarz, N, Scheuplein, F, Rothenburg, S, Haag, F, Alzogaray, V, Cauerhff, A & Goldbaum, FA 2007, 'Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo', FASEB Journal, vol. 21, no. 13, pp. 3490-3498. https://doi.org/10.1096/fj.07-8661com
Koch-Nolte, Friedrich ; Reyelt, Jan ; Schößow, Britta ; Schwarz, Nicole ; Scheuplein, Felix ; Rothenburg, Stefan ; Haag, Friedrich ; Alzogaray, Vanina ; Cauerhff, Ana ; Goldbaum, Fernando A. / Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. In: FASEB Journal. 2007 ; Vol. 21, No. 13. pp. 3490-3498.
@article{bfc89d4122dd42d7bd831b50c697987e,
title = "Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo",
abstract = "The purpose of our study was to develop a tool for blocking the function of a specific leukocyte ecto-enzyme in vivo. ART2.2 is a toxin-related ectoenzyme that transfers the ADP-ribose moiety from NAD onto other cell surface proteins. ART2.2 induces T cell death by activating the cytolytic P2 X 7 purinoceptor via ADP-ribosylation. Here, we report the generation of ART2.2-blocking single domain antibodies from an immunized llama. The variable domain of heavy-chain antibodies (VHH domain) represents the smallest known antigen-binding unit generated by adaptive immune responses. Their long CDR3 endows VHH domains with the extraordinary capacity to extend into and block molecular clefts. Following intravenous injection, the ART2.2-specific VHH domains effectively shut off the enzymatic and cytotoxic activities of ART2.2 in lymphatic organs. This blockade was highly specific (blocking ART2.2 but not the related enzymes ART1 or ART2.1), rapid (within 15 min after injection), and reversible (24 h after injection). Our findings constitute a proof of principle that opens up a new avenue for targeting leukocyte ecto-enzymes in vivo and that can serve as a model also for developing new antidotes against ADP-ribosylating toxins.",
keywords = "ADP-ribosylation, Enzyme inhibitors, Leukocyte ecto-enzymes, Recombinant antibodies",
author = "Friedrich Koch-Nolte and Jan Reyelt and Britta Sch{\"o}{\ss}ow and Nicole Schwarz and Felix Scheuplein and Stefan Rothenburg and Friedrich Haag and Vanina Alzogaray and Ana Cauerhff and Goldbaum, {Fernando A.}",
year = "2007",
month = "11",
doi = "10.1096/fj.07-8661com",
language = "English (US)",
volume = "21",
pages = "3490--3498",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "13",

}

TY - JOUR

T1 - Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo

AU - Koch-Nolte, Friedrich

AU - Reyelt, Jan

AU - Schößow, Britta

AU - Schwarz, Nicole

AU - Scheuplein, Felix

AU - Rothenburg, Stefan

AU - Haag, Friedrich

AU - Alzogaray, Vanina

AU - Cauerhff, Ana

AU - Goldbaum, Fernando A.

PY - 2007/11

Y1 - 2007/11

N2 - The purpose of our study was to develop a tool for blocking the function of a specific leukocyte ecto-enzyme in vivo. ART2.2 is a toxin-related ectoenzyme that transfers the ADP-ribose moiety from NAD onto other cell surface proteins. ART2.2 induces T cell death by activating the cytolytic P2 X 7 purinoceptor via ADP-ribosylation. Here, we report the generation of ART2.2-blocking single domain antibodies from an immunized llama. The variable domain of heavy-chain antibodies (VHH domain) represents the smallest known antigen-binding unit generated by adaptive immune responses. Their long CDR3 endows VHH domains with the extraordinary capacity to extend into and block molecular clefts. Following intravenous injection, the ART2.2-specific VHH domains effectively shut off the enzymatic and cytotoxic activities of ART2.2 in lymphatic organs. This blockade was highly specific (blocking ART2.2 but not the related enzymes ART1 or ART2.1), rapid (within 15 min after injection), and reversible (24 h after injection). Our findings constitute a proof of principle that opens up a new avenue for targeting leukocyte ecto-enzymes in vivo and that can serve as a model also for developing new antidotes against ADP-ribosylating toxins.

AB - The purpose of our study was to develop a tool for blocking the function of a specific leukocyte ecto-enzyme in vivo. ART2.2 is a toxin-related ectoenzyme that transfers the ADP-ribose moiety from NAD onto other cell surface proteins. ART2.2 induces T cell death by activating the cytolytic P2 X 7 purinoceptor via ADP-ribosylation. Here, we report the generation of ART2.2-blocking single domain antibodies from an immunized llama. The variable domain of heavy-chain antibodies (VHH domain) represents the smallest known antigen-binding unit generated by adaptive immune responses. Their long CDR3 endows VHH domains with the extraordinary capacity to extend into and block molecular clefts. Following intravenous injection, the ART2.2-specific VHH domains effectively shut off the enzymatic and cytotoxic activities of ART2.2 in lymphatic organs. This blockade was highly specific (blocking ART2.2 but not the related enzymes ART1 or ART2.1), rapid (within 15 min after injection), and reversible (24 h after injection). Our findings constitute a proof of principle that opens up a new avenue for targeting leukocyte ecto-enzymes in vivo and that can serve as a model also for developing new antidotes against ADP-ribosylating toxins.

KW - ADP-ribosylation

KW - Enzyme inhibitors

KW - Leukocyte ecto-enzymes

KW - Recombinant antibodies

UR - http://www.scopus.com/inward/record.url?scp=35948991091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948991091&partnerID=8YFLogxK

U2 - 10.1096/fj.07-8661com

DO - 10.1096/fj.07-8661com

M3 - Article

C2 - 17575259

AN - SCOPUS:35948991091

VL - 21

SP - 3490

EP - 3498

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 13

ER -